Literature DB >> 21225774

Tonsillar carcinoma in the contralateral tonsil.

Raymond O Smith1, Krishna Pokala, Jesus E Medina, Greg A Krempl.   

Abstract

OBJECTIVE: We report a series of patients treated for carcinoma of the tonsil who either presented with bilateral carcinomas or later developed a second primary carcinoma of the contralateral tonsil. This report raises awareness of this occurrence. STUDY
DESIGN: Case series.
METHODS: Four cases have been identified of either concomitant or subsequent carcinoma of the contralateral tonsil inpatients treated for tonsillar carcinoma from the practices of 3 head and neck surgeons in a single demographic area over a 35 year span.
RESULTS: Four patients were identified who were treated for tonsillar carcinoma with concomitant or subsequent carcinoma of the contralateral tonsil: One patient with bilateral metastatic carcinoma in cervical lymph nodes was found to have bilateral occult tonsillar primaries.Three patients who were treated for tonsillar primary carcinomas subsequently developed carcinoma of the contralateral tonsil.
CONCLUSIONS: A small population of patients with unilateral tonsil carcinoma will developed a second in the contralateral tonsil. This raises the question of whether removal of the contralateral tonsil at the time of initial treatment might have spared the morbidity/mortality of the subsequent contralateral tonsil cancer.

Entities:  

Mesh:

Year:  2010        PMID: 21225774     DOI: 10.1002/lary.21640

Source DB:  PubMed          Journal:  Laryngoscope        ISSN: 0023-852X            Impact factor:   3.325


  2 in total

1.  Severe prolonged dysphagia following transoral resection of bilateral synchronous tonsillar carcinoma.

Authors:  Alpen B Patel; Michael L Hinni; Taylor R Pollei; Richard E Hayden; Eric J Moore
Journal:  Eur Arch Otorhinolaryngol       Date:  2015-02-08       Impact factor: 2.503

Review 2.  Synchronous bilateral tonsil carcinoma: case presentation and review of the literature.

Authors:  M-N Theodoraki; J A Veit; T K Hoffmann; J Greve
Journal:  Infect Agent Cancer       Date:  2017-06-26       Impact factor: 2.965

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.